Clinical Trial Update: Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety of combining rapamycin with irinotecan in pediatric patients with refractory solid tumors; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Irinotecan (Irinotecan)
• Rapamycin (sirolimus)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Refractory Solid Tumors in Children | Phase 1 | Status: COMPLETED